39 results on '"Baile, Mónica"'
Search Results
2. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
3. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
4. CT-169 Cytokine Release Syndrome After Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide: Time of Onset Matters
5. MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience
6. ABCL-297 Hemophagocytic Lymphohistiocytosis Singularity: A Multicenter Retrospective Study
7. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL
8. CT-513 Pure Red Cell Aplasia in Major ABO-Incompatible Allogenic Stem Cell Transplantation: Retrospective Analysis From a Single-Center Experience
9. POSTER: CT-513 Pure Red Cell Aplasia in Major ABO-Incompatible Allogenic Stem Cell Transplantation: Retrospective Analysis From a Single-Center Experience
10. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
11. Low‐risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
12. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
13. Accuracy and prognostic impact of FDG PET / CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation‐Wide cohort study
14. Poster: ABCL-297 Hemophagocytic Lymphohistiocytosis Singularity: A Multicenter Retrospective Study
15. Poster: CT-169 Cytokine Release Syndrome After Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide: Time of Onset Matters
16. P-112: Anti-BCMA therapy in multiple myeloma: a single-center experience
17. Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group
18. Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation‐Wide cohort study.
19. Additional file 1 of Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
20. Worldwide Examination of Patients with CLL Hospitalized for COVID-19
21. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
22. Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic
23. A Case of Paraneoplastic Cerebellar Degeneration that Preceded the Diagnosis of Classical Hodgkin’s Lymphoma by 16 Months
24. Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma
25. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO).
26. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma
27. Assessment of Bone Marrow Infiltration and Minimal Residual Disease by Multidimensional Flow Cytometry in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
28. Multiparametric Flow Fytometry Is More Useful Than Cytology As a Diagnostic Tool for Endoscopic and Transbronchial Ultrasound-Guided Fine Needle Aspiration Samples in Hematological Malignancies: A Single Center Experience
29. Lenalidomide in Combination with R-ESHAP (LR-ESHAP) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Candidates for Autologous Stem-Cell Transplantation: A Phase 2 Study from the Spanish Group Geltamo
30. Poster: MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience
31. Differential prognostic impact of GELTAMO‐IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
32. Bone marrow biopsy superiority over PET/ CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.
33. Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials
34. Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy
35. Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era
36. Hemorrhagic Cystitis in Haploidentical Hematopoietic STEM CELL Trasplant: Retrospective Study and Comparison with a NON-Haploidentical DONOR Transplant Group
37. Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Therapy Related Myeloid Neoplasms: Comparative Study with a De Novo Myeloid Neoplasms Group
38. Prognostic Impact, Phenotypic and Molecular Characterization of Concordant and Discordant Bone Marrow Involvement in Patients with Diffuse Large b-Cell Lymphoma
39. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.